Editorial Policies

Focus and Scope

Trends in Immunotherapy is an open access, peer-reviewed journal encompassing various disciplines related to the immune-based therapeutic method. The journal covers all areas of immunotherapy including:

  1. Cancer immunotherapy
  2. Immunomodulators
  3. Antibodies
  4. Allergy disorder and immunotherapy
  5. Therapeutic method for auto-immune disorder
  6. Immunotherapy cell-products
  7. Cytokines application
  8. Immuno-modulatory effects of natural products

Preliminary studies, pre-clinical and clinical investigative reports are welcomed. The journal accepts original research article, review article, case reports and short communications.

 

Section Policies

Editorial

Editorial reflects the opinion of an Editorial Board member or staff for particular Journal highlighting recent changes, concerned issues or announcements in relevance to the journal. This may include editorial management and policies.

Unchecked Open Submissions Checked Indexed Unchecked Peer Reviewed

Case Report

Case report is a detailed description on rare diseases, novel occurrences, unusual indication or symptoms of a disease, unreported studies or unexpected events observed in a patient during the course of treatment. The study should highlight and report new cases in diagnosis of emerging diseases or specify variations and associations with new diseases. Case report should contain educational values and emphasize on the need of amendments to usual practices and approaches in the field. Case reports should comprise different findings with updated review on previous cases and investigation in the field. There should not be any preventive and therapeutic intrusions in the Case reports from the findings since they need more confirmed evidences.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Commentary

Commentary is short account commissioned by the Editorial board and call for attention on the current issues confined to a particular subject area while sometimes unsolicited articles are accepted from contemporary scientists or experts in the field. The context is to analyze the issues of interest to readers or a discussion on current research and recently published articles in the Journal. Commentaries may also include editorial opinion relevant to scope of the Journal and discuss external implications such as new technology, grant applications, peer reviewing process on research.

Checked Open Submissions Checked Indexed Unchecked Peer Reviewed

Correspondence Article

Correspondence article is letter addressed to the Editor with a short comment on topical issues or reader’s reaction corresponding to an informal publication previously published in the journal. Usually correspondences will not be peer reviewed and should not contain technical comments on research articles or principal research data.

Checked Open Submissions Checked Indexed Unchecked Peer Reviewed

Database Article

Database article should contain vast biomedical information made available to wide utility, accessibility for the retrieval of data.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Mini-review

Mini-review is summarized descriptions based on one or more recent findings and significant developments at particular subject area of research considering the Journal’s scope. It is usually commissioned to create interest on the work and warrant further commentaries on the published articles. Maximum length is 2500 words.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Original Research Article

Original research article should contain completely new principal research testifying major contributions to the field. The study should represent new findings or discoveries in a subject area that were not published before. The report may contain significant findings, methodology importance and considerable evidence to the conclusions.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Perspective Article

Perspective article describes new or potentially unconventional point-of-views on existing clinical observations.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Review Article

Review article is summarized descriptions of recent findings and significant developments at particular subject area of research considering the Journal’s scope. They should include critical assessments of novel technologies, evaluation of subject advancement, elucidate unresolved questions, comparative analysis with a substantial coverage of previous works and highlight future prospects. Although there are no restrictions with the length and content of a review, authors should consider drawing reader’s attention and interest with quality information.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Short Report

Short report is a helpful description on particular area of research confirming the results from previously published articles. The presentation should be in a way of extension to the previous research work with confirmatory results and evidences on negative results, clinical studies or even patients from a same family. Short report should provide the advancement in control to previous work. The basis and motivation for the work submitted as short report should be acknowledged.

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

All manuscripts submitted to the Trends in Immunotherapy are subjected to a stringent peer review process. This is to uphold the high quality of papers published in this journal and ensure that the reporting of research work is truthful and precise.

  1. All submitted manuscript are firstly handled by our managing editor, who will check the manuscript for plagiarism, in which rejection of the manuscript can take place at this stage by the managing editor if plagiarism occurs in the manuscript.
  2. After the plagiarism check is completed and results are deemed satisfactory, the managing editor will pass the manuscript to the Editor-in-Chief who will undertake the peer review process, or at times pass the task to one of the Associate Editors.
  3. A minimum of 2 reviewers will be selected from the pool of reviewers available according to their expertise and suitability to the subject matter of the manuscript. Reviewers will have to give their comments and recommendations (Accept, Revisions Required, Resubmit for Review or Reject) to the Editor-in-Chief or Associate Editor for them to make a final decision on the paper, and their comments will help the authors improve their papers.
  4. Upon recommendations by the reviewers, the Editor-in-Chief or the Associate Editor can make a final decision on the paper and inform the author on their decision, adding comments to the Authors to make improvements in their research or paper.
    • If the decision is to Accept Submission (no amendments required by author), the manuscript will be sent to the Editing stage.
    • If Editor-in-Chief suggests Revisions Required (minor revisions), authors are given a maximum of 2 weeks to revise and resubmit the article.
    • If Editor-in-Chief suggests Resubmit for Review (major revisions), authors are given a maximum of 4 weeks to revise and resubmit the article for the second round of review.
    • If the decision is to Reject Submission, the author will be notified and the rejected manuscript will be archived and the peer review process ends.
  5. An accepted paper will be sent for Copy Editing, Layout Editing and Proofreading before publication. Correspondence between the authors and editors will be required here in order to improve the language and/or look of the manuscript. After the Editing stage is completed, authors are required to check the PDF file of the final version before the article is published. EnPress Publisher registers DOI for the manuscript after publication, in which the article is immediately accessible to the public.
  6. Authors may appeal for a rejected submission. Appeal requests must be made in writing to contact@enpress-publisher.com with detailed reasons for the appeal and point by point responses to the reviewers’ remarks. Decisions on appeals are final and no further consideration will be made.

 

Open Access Policy

This journal provides immediate Open Access to its content as it believes that making research freely available to the public which helps promoting the research results benefiting the scholarly community.

  • Higher Visibility, Availability and Citations – free and unlimited accessibility of the publication over the internet without any restrictions increases citation of the article
  • Ease of search – publications are easily searchable in search engines and indexing databases
  • Rapid Publication – accepted papers are immediately published online

 

Editorial Policies

Authors should read the “Author Guidelines” before making a submission, and make sure that the manuscripts were written in accordance to the style and specifications of the journal’s policy.

All manuscripts submitted toTrends in Immunotherapy are subject to rigorous peer review. Prior to peer review process, the manuscripts will be screened for acceptable English language, novelty and relevance to the Focus and Scope of the journal.

Any manuscripts submitted toTrends in Immunotherapy will be treated as confidential materials. The manuscripts will not be disclosed to anyone except individuals such as editorial staff, reviewers and editors who participate in the initial screening, review, processing and preparation of the manuscript for publication (if accepted).

A manuscript would not be considered if it has been published or is currently under consideration for publication in any other journals. In the cover letter, authors must state that neither the manuscript nor any significant part of it is under consideration for publication elsewhere or has appeared elsewhere in a manner that could be construed as a prior or duplication of the same work. The authors are required to notify the editorial team if the findings and data in their submissions have been presented in conferences.

 

Authorship

Authorship of a scholarly paper should be limited to individuals who have contributed substantially to its intellectual content. Participation solely in the acquisition of funding or general supervision of the research group is not sufficient for authorship. All authors should hold the responsibility of fairly evaluating their respective roles and their co-authors’ roles in the project. This is to ensure that authorship is attributed according to a fixed standard in all publications for which they will be listed as authors.

In order to be listed as an author for a paper, one should have contributed sufficiently in the project. A co-author is expected to have contributed to some component of the work which led to the paper, or be involved in interpretation of its results. All authors should have a say in the final approval of the version to be published, in addition to reviewing the final manuscript prior to submission.

Individuals who do not meet the above requirements, but have provided a valuable contribution to the work, may be acknowledged for their contribution as appropriate to the publication.

 

Publication Frequency

The publication frequency of Trends in Immunotherapyis

bi-annual.

 

Conflict of Interest

Conflicts of interest may exist when professional judgements concerning a primary interest has the possibility of being influenced by a secondary interest (e.g.: financial gains). It is to be noted that even perceptions of conflicts of interest are as important as the actual conflicts of interest.

Any agreements with study sponsors (for profit or non-profit), which interfere with the authors’ access to the study data, ability to analyse or interpret the data and publish manuscripts independently according to their own decision, should be avoided by authors at all costs.

A declaration of interests for all authors must be received before an article can be reviewed and accepted for publication.

 

Plagiarism

Authors are advised to perceive high standards in the aspect of publication ethics. Any plagiarism (fabrication or falsification of data) are strictly unacceptable practices in Trends in Immunotherapy, including duplicate publication of the author’s work without proper citation.

Every manuscript submitted for publication is checked for plagiarism via CrossCheck (powered by iThenticate) after submission and before being sent to the editor for editorial review. Any detection of overlapping and similar texts in the manuscripts submitted will be investigated promptly and may lead to the manuscript being rejected.

 

Article Processing Charges

The article processing charges are meant to support the journal’s associated expenses. The editorial team will have the right to assume that authors submitting their manuscripts for publication consents to paying the publication fee upon acceptance for publication.

Refer to http://enpress-publisher.com/journals/ti/apc/ for details.

 

Language

The language used in manuscripts submitted to Trends in Immunotherapy is English. Authors whose first language is not English may want to have their manuscripts professionally edited before the final submission to ensure that the academic content of the paper is fully understood by its prospective readers.

 

Permission and Reprints

Any part of materials published in Trends in Immunotherapy may not be reproduced without written permission of the publisher. Please click here to write in the permission request.

 

Publishing Ethics

This Journal requests all members involved in the journal publishing process to adhere to the Core Practices on publication ethics as stipulated by Committee on Publication Ethics (COPE) in compliance with the information and guidelines on handling publishing ethics allegations as described in the Publishing Ethics Resource Kit (PERK).

The journal editors take all possible misconducts seriously. The Editors, authors or readers can forward their concerns to the journal if they find out that the description in a submitted article may constitute an academic fraud, research misconduct or publication malpractice. The concerns or complaints on the possible allegations submitted to the journal will be dealt with promptly and appropriately according to the procedure set out in the COPE flowchart on complaints and in PERK. The complainant may direct all inquiries and correspondence to the Publisher at editor@enpress.com.

This Journal adopts a zero-tolerance policy concerning any academic misconducts and ethical violations in research and publication regardless of the severity of these issues. The violations include plagiarism, falsification of research, data fabrication, submitting manuscripts of others as one’s own, submission of same manuscript to different publication venues at the same time and breached intellectual property rights. In cases of suspected misconduct and ethical violation, a panel will be formed to investigate the allegation. If the allegation is supported by evidence, the submitted manuscript in question will be declined for consideration in the journal and all authors will be informed in this regard. A retraction initiated by authors or by the journal is required to take place if the paper has already been published, and the retraction will be made public. Authors of the work in question will receive the Panel’s Decision via email and all appeals regarding the decision will have to be made to the Publisher at editor@enpress.com within 28 days of the decision date.

 

Preprint Policy

Authors are permitted to post their non-peer-reviewed original research manuscripts to community preprint servers such as bioRxiv, medRxiv, and PeerJ Preprint before or in parallel with the formal submission to the Trends in Immunotherapy. During submission, authors are obliged to declare in the cover letter if the corresponding preprint version of their submission has been deposited on a preprint server, and provide any associated accession numbers or DOIs.

Nonetheless, authors are not allowed to post any versions of articles that have been revised as a result of peer review, accepted for publication or published in the journal on a preprint server. The manuscript whose corresponding preprint version has been indexed (e.g. in MEDLINE or PubMed) will not be considered.

This policy applies to original research papers only. This journal  reserves the right not to consider for publication or publish material that has been formally published in digital media that shall not be construed as preprint servers.

We encourage formal citation of preprints in the reference list, where appropriate.

 

Changes to Authorship

The authors should carefully check the list and order of authors before submitting their manuscript. The Editorial Office considers the authorship list is definitive by the time the original submission is received.

Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript is accepted for publication. The corresponding author should provide the reasons for the change in authorship list and the proof of written confirmation from all authors (including the existing authors, author(s) to be added and/or removed) agreeing with such change, to the Editorial Office.

The requests for authorship changes need to be approved by the Editorial Office before any changes can be made.

 

Withdrawal Policy

If you decide to withdrawal your manuscript after it has been accepted (but not yet published), a processing fee of USD 200 is chargeable upon withdrawal.

 

Disclaimer

This journal  is not liable to the statements, perspectives, and opinions contained in the published articles. The appearance of advertisements in the journal shall not be construed as a warranty, endorsement, or approval of the products or services advertised and/or the safety thereof. This journal and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

 

Copyright and License

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

All articles published by theTrends in Immunotherapy are licensed under the Creative Commons International Licenses. Without any explicit request from the corresponding author during submission stage, a paper will be published under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) by default. The authors who would like to publish their work under a more accommodating license, i.e. Creative Commons Attribution 4.0 International License (CC BY 4.0), they should express explicit request during submission stage. Please include statement below in the Comments for the Editor column on the submission page:

The contributors or authors for this submission entitled “[MANUSCRIPT TITLE]”, i.e. [NAMES of ALL AUTHORS], have given their consents to alter the Creative Commons license to *CC BY 4.0* under which this submission will be published in Trends in Immunotherapy.

 

 

Advertising Policy

All advertisements are subject to approval to the Publisher. Advertisements must comply with the relevant regulations in the country where the advertisements appear. For more inquiries, please send email to editor@enpress.com.

 

Human Research

If human subjects were used in the experiments, authors must identify the committee or organization (e.g. author’s Institutional Ethics Review Board) approving the experiments in the Methodology section of the manuscript, which should also detail ethics approval information such as the name of the granting committee or organization and the approval identifiers, i.e. reference numbers. This journalrequires that authors provide a proof of research ethics or ethics statement along with the submission. In the case that ethics approval identifiers are not available, written approval from the granting committee or organization must be provided as confidential supplemental file.

In the manuscript, include a statement in the Methodology section confirming that the experiments were carried out in adherence to the ethical principles set out in the WMA Declaration of Helsinki and that informed consent was obtained from all human subjects. 

For investigations undertaken on human subjects, the manner in which the informed consent was obtained from the study participants (i.e., oral or written) should be stated clearly as well.

The authors should inform the study participants of the purpose(s) of publication, the possible risks and benefits as a result of the experiment, and the patient's right to withhold or withdraw consent. Consent should be obtained from the parent(s) or legal guardian(s) if the study participant is a minor.

Authors are obliged to declare and clearly specify any restrictions on the availability or the use of human data in the manuscript.

Authors are encouraged to follow the CARE guidelines while reporting a clinical case that involves the use bioprinted construct on human subject. If the article reporting guidelines suggested by the Trends in Immunotherapy were not pertinent to your work, please look for and refer to the appropriate reporting standards as found on EQUATOR Network, which have been adopted by the field of the works or which apply to their study design.

 

Patient Anonymity and Privacy

Human subjects have a right to privacy that should not be violated without informed consent. Identifying information or patient identifiers, including patient names, initials, date of birth, contacts, medical record numbers, hospital numbers, and geographical location, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Efforts must be made by the authors to at least mask or conceal any identifying information of the patients that appear in writing or within photograph.

Authors are obliged to explain to the patient if revealing the patient’s identity cannot be fully avoided, e.g. an image of an identifiable body part like the face has to be published in the report. The relevant identifying information to be published, e.g. the image, must be shown to the patient, and consent for publication taken for the use of that information in the publication. If the patient dies, then consent must be obtained from next of kin or legal representative. Authors may consider using our sample Consent Form for Publication in the Trends in Immunotherapy. This journal  shall consider author version of consent form for publication if all the essential items as shown in our sample consent form were included.

All submissions will be checked for documentation of patient consent for publication and for any potentially identifying information. Submissions that include identifying patient information without appropriate patient consent will not be considered for publication.

Refer to ICMJE Privacy and Confidentiality guidelines for more information about patient anonymity and privacy.

 

Animal Research

For studies reporting experiments that involve testing on regulated animals (i.e. all live vertebrates and/or higher invertebrates), authors must identify the committee or organization (e.g. author’s Institutional Ethics Review Board) approving the experiments in the Methodology section of the manuscript, which should also detail ethics approval information such as the name of the granting committee or organization and the approval identifiers, i.e. reference numbers. For research conducted on non-regulated animals, a statement should be made as to why ethical approval was not required.

This journal requires that authors provide a proof of research ethics or ethics statement along with the submission. In the case that ethics approval identifiers are not available, written approval from the granting committee or organization must be provided as confidential supplementary file.

Authors are encouraged to follow the ARRIVE guidelines while reporting animal research. In the manuscripts, any additional guidelines for the care and use of laboratory animals that were used in the experiment should be indicated. Briefly, the authors should also include animal details (e.g. species, gender, age, weight), animal housing conditions and husbandry information, and relevant steps taken to ameliorate pain and suffering of the animals in the Methodology section.

Specifically, experiments on non-human primates must be performed in accordance with the recommendations set out in the Weatherall report (The Use of Non-Human Primates in Research).

 

 

Article Processing Charges (APC)

Enpress publishes all its journals in Gold Open Access format. The scientific community and the general public have free of all restrictions on accessing (e.g., subscription) and free of many restrictions on using its contents as soon as it is published online. Enpress does not require readers to purchase any form of subscription to view online versions of the journals. In order to defray our editorial and production costs, authors of the accepted articles are required to pay the article processing charges (APCs). The charges will come from authors' institutes or research funding bodies.

Journal

APC

Trends in Immunotherapy

US $800

 

Indexing

Trends in Immunotherapy is indexed, cataloged and/or included by several world-class abstracting/indexing databases:

CNKI Scholar (中国知网)

Crossref

Google Scholar

National Library Board of Singapore

Scilit

Worldcat 








contact us

14701 Myford Road, Suite B-1, Tustin, CA 92780, United States
Tel:+1 (949) 299 0192